BillionToOne Inc (BLLN) Stock Price, Trades & News

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	3.73
Equity-to-Asset	0.72
Debt-to-Equity	0.29
Debt-to-EBITDA	3.42
Interest Coverage	556.49
Piotroski F-Score	N/A/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	18.06	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	122.35
	Future 3-5Y Total Revenue Growth Rate Estimate	32.57

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	82.03
	9-Day RSI	73.64
	14-Day RSI	68.28
	3-1 Month Momentum %	25.4
	6-1 Month Momentum %	20.96

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	10.92
	Quick Ratio	10.58
	Cash Ratio	9.4
	Days Inventory	59.02
	Days Sales Outstanding	43.24
	Days Payable	27.51

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	-0.14

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.4
	Operating Margin %	10.2
	Net Margin %	8.3
	EBITDA Margin %	11.88
	FCF Margin %	7.43
	OCF Margin %	10.55
	ROE %	23.72
	ROA %	5.96
	ROIC %	29.12
	ROC (Joel Greenblatt) %	33.06
	ROCE %	6.76
	Years of Profitability over Past 10-Year	1
	Moat Score	3

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PE Ratio	255.92
	Forward PE Ratio	124.42
	PE Ratio without NRI	255.92
	PS Ratio	16.3
	PB Ratio	11.12
	Price-to-Tangible-Book	11.12
	Price-to-Free-Cash-Flow	224.02
	Price-to-Operating-Cash-Flow	157.48
	EV-to-EBIT	173.17
	EV-to-EBITDA	124.28
	EV-to-Revenue	14.76
	EV-to-FCF	198.58
	Price-to-Graham-Number	11.25
	Price-to-Net-Current-Asset-Value	13.11
	Price-to-Net-Cash	16.42
	Earnings Yield (Greenblatt) %	0.58
	FCF Yield %	0.47

Financials (Next Earnings Date:2026-08-31 Est.)

Annual Quarterly TTM

BLLN's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:BLLN

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

BillionToOne Inc Executives

Details

GF Value™

BLLN

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with BLLN. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	354.537
	EPS (TTM) ($)	0.478
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	-
	14-Day RSI	68.28
	14-Day ATR ($)	7.176442
	20-Day SMA ($)	104.185
	12-1 Month Momentum %	-
	52-Week Range ($)	61.96 - 138.7
	Shares Outstanding (Mil)	46

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	9999
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

BillionToOne Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

BillionToOne Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-30	In 152 days
Third quarter earnings results for 2026	2026-11-30	In 152 days
Second quarter earnings conference call for 2026	2026-08-31	In 61 days
Second quarter earnings results for 2026	2026-08-31	In 61 days
General meeting for 2026	2026-06-10 09:00	102.39 (+6.47%)
William Blair 46th Annual Growth Stock Conference.	2026-06-02 12:40	91.12 (-7.02%)
First quarter earnings conference call for 2026	2026-05-06 13:30	79.90 (+10.96%)
First quarter earnings results for 2026	2026-05-06	79.90 (+10.96%)
Annual report for 2026	2026-03-11	70.20 (-2.65%)
Fourth quarter earnings conference call for 2025	2026-03-04 16:30	83.14 (+5.87%)

Show

Entries

BillionToOne Inc Frequently Asked Questions

What is BillionToOne Inc(BLLN)'s stock price today?

The current price of BLLN is $122.33. The 52 week high of BLLN is $138.70 and 52 week low is $61.96.

When is next earnings date of BillionToOne Inc(BLLN)?

The next earnings date of BillionToOne Inc(BLLN) is 2026-08-31 Est..

Does BillionToOne Inc(BLLN) pay dividends? If so, how much?

BillionToOne Inc(BLLN) does not pay dividend.

Guru Commentaries on NAS:BLLN

No articles.

Press Release

	Subject	Date
	BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study	2026-06-29
	BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics	2026-05-01
	BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology	2026-04-02
	BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®	2026-02-10
	BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care	2026-02-09
	BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare	2026-01-15
	BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East	2026-01-06
	BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair	2025-12-09
	Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering	2025-11-06

10/Page

Articles on BillionToOne Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.